Evaluation of an anthroposophic supportive treatment intervention (ASTI) in children with malignant diseases during intensive chemotherapy

Supportive mistletoe therapy in a patient with metastasised neuroblastoma

“…This observation reinforces the significance of mistletoe therapy as a supportive treatment in oncology, which is primarily intended to restore well-being and performance during and following conventional therapy. With regard to children and adolescents, the effectiveness of this therapy as an element of oncological treatment, rehabilitation and aftercare should be tested in a clinical study with an appropriate number of patients focusing on mistletoe therapy, as the multicentre study,13 cited at multiple junctures above, only allowed statements about the overall supportive concept proven involving mistletoe therapy but not about mistletoe therapy itself.…”

“…In April 2011, the patient began a regimen of anthroposophic supportive therapy, which has shown its value in the previously mentioned randomised multicentre phase IV trial 13. The therapy concept, in this case, revolved around the subcutaneous injection of the mistletoe product Helixor A, with an initial dose of 1.25 mg (0.25 mL Helixor A 5 mg).…”